Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks.
Histone deacetylase 3 (Hdac3) is an enzymatic component of transcriptional repression complexes recruited by the nuclear hormone receptors. Inactivation of Hdac3 in cancer cell lines triggered apoptosis, and removal of Hdac3 in the germ line of mice caused embryonic lethality. Therefore, we deleted Hdac3 in the postnatal mouse liver. These mice developed hepatomegaly, which was the result of hepatocyte hypertrophy, and these morphological changes coincided with significant imbalances between carbohydrate and lipid metabolism. Loss of Hdac3 triggered changes in gene expression consistent with inactivation of repression mediated by nuclear hormone receptors. Loss of Hdac3 also increased the levels of Ppar gamma2, and treatment of these mice with a Ppar gamma antagonist partially reversed the lipid accumulation in the liver. In addition, gene expression analysis identified mammalian target of rapamycin signalling as being activated after deletion of Hdac3, and inhibition by rapamycin affected the accumulation of neutral lipids in Hdac3-null livers. Thus, Hdac3 regulates metabolism through multiple signalling pathways in the liver, and deletion of Hdac3 disrupts normal metabolic homeostasis.
Knutson
Sarah K
SK
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Chyla
Brenda J
BJ
Amann
Joseph M
JM
Bhaskara
Srividya
S
Huppert
Stacey S
SS
Hiebert
Scott W
SW
D000107:Acetylation / Q000187:drug effects; D000818:Animals; D000831:Animals, Newborn; D002784:Cholesterol / Q000096:biosynthesis; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D017353:Gene Deletion; D005786:Gene Expression Regulation / Q000187:drug effects; D053263:Gene Regulatory Networks / Q000187:drug effects; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology; D006655:Histone Deacetylases / Q000172:deficiency* / Q000378:metabolism; D006706:Homeostasis / Q000187:drug effects; D006984:Hypertrophy; D007003:Hypoglycemia / Q000201:enzymology; D007328:Insulin / Q000097:blood; D019426:Integrases / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D051379:Mice; D009928:Organ Specificity / Q000187:drug effects; D047495:PPAR gamma / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases; D000099186:Histone Deacetylase 3
D002784:Cholesterol; D004791:Enzyme Inhibitors; D006655:Histone Deacetylases; D007328:Insulin; D019426:Integrases; D047495:PPAR gamma; D011494:Protein Kinases; D058570:TOR Serine-Threonine Kinases; D000099186:Histone Deacetylase 3; C546843:mTOR protein, mouse; C045073:Cre recombinase